SMMT
Summit Therapeutics Inc.
NASDAQ · Healthcare · Biotechnology · US
$17.61
+2.77%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | 583.2K |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | 583.2K |
| Operating Expenses | |||||
| R&D Expense | 568.7M | 537.7M | 132.4M | 455.3M | 43.0M |
| SG&A Expense | 306.1M | 556.7M | 48.3M | 23.7M | 22.1M |
| General & Admin Expense | 306.1M | 556.7M | 48.3M | 23.7M | 22.1M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | (250.3K) | (785.8K) | (4.9M) |
| Total Operating Expenses | 874.8M | 1.1B | 180.5M | 478.2M | 60.2M |
| Cost and Expenses | 874.8M | 1.1B | 180.5M | 478.2M | 60.2M |
| Operating Income (EBIT) | (874.8M) | (1.1B) | (180.5M) | (478.2M) | (59.6M) |
| Non-Operating | |||||
| Interest Income | 18.9M | 15.5M | 13.5M | 10.4M | 1.5M |
| Interest Expense | — | — | 8.7M | 16.5M | 4.4M |
| Net Interest Income | 18.9M | 15.5M | 4.8M | (6.1M) | (2.9M) |
| Other Non-Op Income/Expense | 18.8M | 14.8M | 3.7M | (4.1M) | (5.5M) |
| Non-Operating Income (excl Interest) | (18.8M) | (14.8M) | (12.0M) | (408.6M) | (7.0M) |
| EBT (Pre-Tax Income) | (856.0M) | (1.1B) | (176.8M) | (482.4M) | (65.2M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (856.1M) | (1.1B) | (176.8M) | (482.4M) | (65.2M) |
| Earnings from Cont. Ops | (856.0M) | (1.1B) | (176.8M) | (482.4M) | (65.2M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (856.1M) | (1.1B) | (176.8M) | (482.4M) | (65.2M) |
| Per Share | |||||
| Basic EPS | ($1.12) | ($1.44) | ($0.25) | ($0.78) | ($0.34) |
| Diluted EPS | ($1.12) | ($1.44) | ($0.25) | ($0.78) | ($0.34) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 778.2M | 747.7M | 713.9M | 619.6M | 192.2M |
| Diluted Shares Outstanding | 778.2M | 747.7M | 718.5M | 619.6M | 193.3M |
| Profitability Metrics | |||||
| EBITDA | (855.9M) | (1.1B) | (168.5M) | (69.5M) | (51.6M) |
| D&A | 128.0K | 146.0K | 71.0K | 155.3K | 1.0M |
| EBIT | (856.0M) | (1.1B) | (168.5M) | (69.6M) | (52.6M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026